The present invention relates to α-asary-laldehyde ester, a preparation method therefor, and an application thereof. The chemical structure of the related α-asary-laldehyde ester is represented by formula I. A related application is an application of the compound in preparation of drugs for calming, mind tranquillizing, senile dementia resisting, convulsion resisting, epilepsy resisting and depression resisting.

The present invention relates to α-asary-laldehyde ester, a preparation method therefor, and an application thereof. The chemical structure of the related α-asary-laldehyde ester is represented by formula I. A related application is an application of the compound in preparation of drugs for calming, mind tranquillizing, senile dementia resisting, convulsion resisting, epilepsy resisting and depression resisting.

An elegant process for the synthesis of 2-nitratoethyl acrylate is a single reactive step. A 2-hydroxyethyl acrylate having only one hydroxyl group is nitrated in a 1:1 volumetric mixture of nitric acid and sulfuric acid therein forming 2-nitratoethyl acrylate. The 2-nitratoethyl acrylate is minimally soluble in a quenched cold acid water mixture, which enables relatively easy isolation of about 96% purity 2-nitratoethyl acrylate at a yield of about 85%.

An elegant process for the synthesis of 2-nitratoethyl acrylate is a single reactive step. A 2-hydroxyethyl acrylate having only one hydroxyl group is nitrated in a 1:1 volumetric mixture of nitric acid and sulfuric acid therein forming 2-nitratoethyl acrylate. The 2-nitratoethyl acrylate is minimally soluble in a quenched cold acid water mixture, which enables relatively easy isolation of about 96% purity 2-nitratoethyl acrylate at a yield of about 85%.

The present invention relates to ?-asary-laldehyde ester. The chemical structure of the related ?-asary-laldehyde ester is of formula I.

The present invention relates to ?-asary-laldehyde ester. The chemical structure of the related ?-asary-laldehyde ester is of formula I.

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.

Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.